查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009203

疫苗契約製造市場規模、佔有率、趨勢和預測：按疫苗類型、工作流程、應用和地區分類，2026-2034 年

Vaccine Contract Manufacturing Market Size, Share, Trends and Forecast by Vaccine Type, Workflow, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2025年全球疫苗契約製造（ CMO）市場規模為33億美元。預計到2034年，該市場規模將達到65億美元，2026年至2034年的複合年成長率（CAGR）為8.03%。北美目前在主導，2025年市佔率達36%。世界各國政府將免疫接種作為公共衛生策略的基石，並透過津貼、補貼和採購合約來確保疫苗的及時供應。此外， 契約製造的擴張也推動了疫苗契約製造市場佔有率的成長。

受感染疾病蔓延、人們對醫療保健日益重視以及為應對未來大流行病做好準備等因素推動，全球對疫苗的需求不斷成長，市場正在蓬勃發展。高昂的研發和生產成本阻礙了製藥和生物技術公司投資建設大規模設施，導致越來越多的企業將生產外包給擁有成熟專業知識和合規能力的契約製造生產商 (CMO)。拓展先進疫苗的開發平臺，包括信使核糖核酸 (mRNA) 和病毒載體平台，需要 CMO 更擅長的專業技術。此外，對靈活可擴展生產能力的需求，以及縮短產品上市時間的壓力，使得外包成為策略選擇。

由於多種因素，美國正崛起為契約製造市場的領先地區。公眾對健康、免疫計劃以及應對新興感染疾病的日益關注，推動了契約製造市場的成長。高昂的研發和生產成本，加上嚴格的監管要求，促使製藥和生物技術公司與經驗豐富的契約製造合作，這些製造商能夠提供合規方面的專業知識、先進的設施和成本效益。隨著美國生物製藥產品線的擴展，包括mRNA疫苗和病毒載體疫苗，對專業技術和靈活的生產能力的需求日益成長，許多公司傾向於將這些業務外包。根據IMARC Group預測，到2033年，美國生物製藥市場規模預計將達到3,710億美元，2025年至2033年的複合年成長率（CAGR）為7.4%。

疫苗契約製造市場的發展趨勢：

人們對疫苗接種的認知不斷提高

人們對疫苗接種的日益關注為契約製造市場創造了有利前景。隨著個人、社區和政府認知到疫苗在預防感染疾病和減輕醫療負擔方面發揮的關鍵作用，全球免疫接種計劃正在不斷擴展。疫苗接種透過減少抗生素的使用和預防疾病，在改善人類和動物健康方面發揮著至關重要的作用。根據世界衛生組織（WHO）預測，截至2024年8月，疫苗接種每年將預防350萬至500萬人死於白喉、破傷風、百日咳、流感和麻疹等疾病。這種日益增強的意識不僅提高了疫苗接種率，也促使製藥和生物技術公司迅速擴大生產規模，而這通常是透過外包給契約製造製造商來實現的。契約製造（CMO）提供所需的專業知識、基礎設施和生產能力，以高效滿足不斷成長的需求，同時確保品質和合規標準。

擴大政府支持

政府支持力度的加強是契約製造市場的關鍵趨勢之一。世界各國政府都將免疫接種作為公共衛生策略的基石，並透過提供津貼、補貼和採購合約來確保疫苗的及時供應。這種支援降低了製藥和生物技術公司的財務風險，使它們能夠將生產外包給擁有先進基礎設施和監管專業知識的專業合約生產機構（CMO）。此外，官民合作關係正在促進創新，提高供應鏈韌性，並擴大全球疫苗的可及性。在緊急情況下，各國政府也正在簡化監管流程，並加速核准和生產進度。這種積極的支持不僅增強了人們對契約製造的信心，也確保了合約生產機構在高效滿足國內外疫苗接種需求方面發揮關鍵作用。根據聯合國兒童基金會在 2025 年 3 月進行的一項宣傳活動效果調查，在衛生署和聯合國兒童基金會開展輪狀病毒疫苗媒體宣傳活動後，94% 的家長和看護者表示對接種疫苗的興趣有所增加，78% 的家長和監護人表示對疫苗的成分有「清晰」或「非常清晰」的了解。

SARS-CoV-2 活性增強

SARS-CoV-2病毒活動加劇，加速了對疫苗、加強針以及旨在應對新出現的變異株的新一代疫苗的需求。根據世界衛生組織的數據，全球SARS-CoV-2病毒活動自2025年2月中旬起持續上升，檢測陽性率達到11%，為2024年7月以來的最高水準。病毒的持續傳播凸顯了大規模、靈活生產能力的重要性，而製藥公司通常透過外包給合約生產商（CMO）來實現這一目標。契約製造生產商具備專業知識和擴充性，能夠快速調整生產流程以適應更新的疫苗，從而確保全球及時供應。病毒變異株的演變以及反覆出現的感染浪潮的不可預測性，使得維持強大的疫苗研發管線變得尤為重要，也進一步增加了對合約生產商的依賴。此外，SARS-CoV-2病毒的出現提高了人們對疫苗研發準備的關注度，並刺激了對mRNA平台等先進技術的投資，而合約生產商在這些技術中發揮著至關重要的作用。根據對契約製造市場的預測，病毒的持續傳播將繼續推動市場擴張。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球疫苗契約製造市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 衰減
  • 失活
  • 次單元類型
  • 類毒素類型
  • 基於DNA的

第7章 市場區隔：依工作流程

  • 下游工藝
    • 主要部分
      • 填充和表面處理工程
      • 分析和品管(QC) 測試
      • 包裝
  • 上游工程
    • 主要部分
      • 哺乳動物表達系統
      • 細菌表現系統
      • 酵母表現系統
      • 桿狀病毒/昆蟲表現系統
      • 其他

第8章 市場區隔：依應用領域分類

  • 對人類而言
  • 獸用

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited（Charles River Laboratories International Inc.）
    • Cytovance Biologics Inc.（Hepalink USA Inc.）
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
Product Code: SR112026A3872

The global vaccine contract manufacturing market size was valued at USD 3.3 Billion in 2025. The market is projected to reach USD 6.5 Billion by 2034, exhibiting a CAGR of 8.03% from 2026-2034. North America currently dominates the market, holding a market share of 36% in 2025. Governments worldwide are prioritizing immunization as a key public health strategy, offering grants, subsidies, and procurement commitments to ensure timely access to vaccines. Besides this, the expansion of contract manufacturing organizations (CMOs) is propelling the vaccine contract manufacturing market share.

The market is being propelled by rising global demand for vaccines, driven by increasing infectious disease prevalence, greater focus on preventive healthcare, and preparedness for future pandemics. High research and production costs often discourage pharmaceutical and biotech firms from investing in large-scale facilities, leading them to outsource to contract manufacturers with established expertise and regulatory compliance capabilities. The expanding pipeline of advanced vaccines, including messenger ribonucleic acid (mRNA) and viral vector platforms, requires specialized technologies that CMOs are better positioned to provide. Additionally, the need for flexible and scalable production capacity, combined with the pressure to reduce time-to-market, is making outsourcing a strategic choice.

The United States has emerged as a major region in the vaccine contract manufacturing market owing to many factors. Rising focus on public health, immunization programs, and preparedness against emerging infectious diseases is propelling the vaccine contract manufacturing market growth. High research and development (R&D) and production costs, along with stringent regulatory requirements, are encouraging pharmaceutical and biotech firms to collaborate with experienced contract manufacturers that offer compliance expertise, advanced facilities, and cost efficiency. The country's growing pipeline of biologics, including mRNA and viral vector vaccines, requires specialized technologies and flexible manufacturing capacities that many firms prefer to outsource. As per the IMARC Group, the United States biologics market is set to attain USD 371.0 Billion by 2033, exhibiting a CAGR of 7.4% from 2025-2033.

VACCINE CONTRACT MANUFACTURING MARKET TRENDS:

Increasing awareness about vaccination

The growing awareness about vaccination is offering a favorable vaccine contract manufacturing market outlook. As individuals, communities, and governments are recognizing the critical role of vaccines in preventing infectious diseases and reducing healthcare burdens, immunization programs are being expanded globally. Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents ailments. According to the WHO, as of August 2024, vaccination averted 3.5 Million to 5 Million fatalities annually from illnesses, such as diphtheria, tetanus, pertussis (whooping cough), influenza, and measles. This heightened consciousness is not only boosting vaccination rates but also encouraging pharmaceutical and biotech companies to scale up production quickly, often through outsourcing to contract manufacturers. CMOs provide the expertise, infrastructure, and capacity needed to meet this increasing demand efficiently while maintaining quality and compliance standards.

Rising government support

Rising government support is among the major vaccine contract manufacturing market trends. Governments worldwide are prioritizing immunization as a key public health strategy, offering grants, subsidies, and procurement commitments to ensure timely access to vaccines. This backing reduces financial risks for pharmaceutical and biotech companies, enabling them to outsource manufacturing to specialized CMOs with advanced infrastructure and regulatory expertise. Additionally, public-private partnerships are fostering innovations, improving supply chain resilience, and expanding global vaccine access. Governments are also streamlining regulatory pathways during emergencies, accelerating approval and production timelines. Such proactive support is not only strengthening confidence in contract manufacturing but also ensuring CMOs play a vital role in meeting both domestic and international vaccination needs efficiently. A UNICEF campaign effectiveness survey conducted in March 2025 found that 94% of parents and caregivers expressed increased interest in vaccination, after the Rota Vaccine media campaign by the Ministry of Health and UNICEF, and 78% reported they understood the vaccine 'clearly' or 'very clearly.'

Increasing SARS-CoV-2 activity

Rising SARS-CoV-2 activity is catalyzing the demand for vaccines, booster shots, and next-generation formulations designed to address emerging variants. According to WHO data, worldwide SARS-CoV-2 activity has been increasing since mid-February 2025, with the test positivity rate attaining 11%, the highest recorded since July 2024. Continued viral circulation highlights the need for large-scale, flexible production capacity that pharmaceutical firms often achieve through outsourcing to CMOs. Contract manufacturers provide the expertise and scalability to rapidly adapt production processes for updated vaccines, ensuring timely global supply. The unpredictability of variant evolution and recurring infection waves is reinforcing the importance of maintaining strong vaccine pipelines, which is further increasing reliance on CMOs. Additionally, SARS-CoV-2 has accelerated awareness about vaccine preparedness and encouraged investments in advanced technologies like mRNA platforms, where CMOs play a pivotal role. As per the vaccine contract manufacturing market forecast, the ongoing viral activity will continue to fuel the market expansion.

VACCINE CONTRACT MANUFACTURING INDUSTRY SEGMENTATION:

Analysis by Vaccine Type:

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Inactivated holds 33.4% of the market share in 2025. These vaccines use killed or non-replicating pathogens, making them safer for individuals with weakened immune systems and suitable for mass immunization programs. Their production process is standardized and well-understood, allowing contract manufacturers to scale up with fewer risks compared to newer or more complex vaccine platforms. Additionally, regulatory bodies worldwide have long experience approving inactivated vaccines, which speeds up licensing and market access. These vaccines are extensively used against influenza, polio, hepatitis A, rabies, and several other infectious diseases, ensuring steady demand from both public and private healthcare providers. CMOs benefit from consistent demand, established production technologies, and the ability to serve large-scale vaccination campaigns, especially in developing regions. Furthermore, inactivated vaccines are often more stable and easier to store and transport compared to some modern alternatives, which supports global distribution.

Analysis by Workflow:

  • Downstream
    • Fill and Finish Operations
    • Analytical and QC Studies
    • Packaging
  • Upstream
    • Mammalian Expression Systems
    • Bacterial Expression Systems
    • Yeast Expression Systems
    • Baculovirus/Insect Expression Systems
    • Others

Downstream (fill and finish operations, analytical and QC studies, and packaging) accounts for 58% of the market share. Downstream processes are critical in ensuring the purity, safety, and effectiveness of vaccines before distribution. While upstream activities focus on cultivation and production, downstream operations, such as purification, filtration, separation, and formulation, ensure that vaccines meet stringent regulatory and quality standards. These processes are often more complex, resource-intensive, and cost-demanding, making them a major contributor to overall manufacturing expenditure. Contract manufacturers with advanced downstream capabilities add value by improving yield, maintaining consistency across large batches, and reducing contamination risks. With rising demand for sophisticated vaccines like mRNA and viral vector platforms, the downstream stage has gained greater importance in handling delicate biomolecules. Its pivotal role in product validation, compliance, and large-scale readiness is driving its dominance in the market, as no vaccine can be commercialized without rigorous downstream processing.

Analysis by Application:

  • Human Use
  • Veterinary

Human use holds 85% of the market share. Human use vaccines are prioritized globally because of their vital function in averting infectious diseases, lowering morbidity and mortality, and supporting public health initiatives. Governments, international health organizations, and private healthcare providers are investing in large-scale immunization programs, creating a continuous need for reliable vaccine supply. Pharmaceutical and biotech companies often rely on contract manufacturers to meet this demand efficiently, leveraging their expertise, advanced facilities, and compliance with stringent regulatory standards. The rising prevalence of infectious diseases, coupled with pandemic preparedness and emerging vaccine technologies, such as mRNA, viral vector, and recombinant platforms, is further intensifying production requirements. While veterinary vaccines are essential, the scale, urgency, and societal impact of human vaccination far exceed other applications, making human use the dominant driver of growth in the market worldwide.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for a share of 36%, enjoys the leading position in the market. The region is noted for its strong biotechnology and pharmaceutical ecosystem, advanced infrastructure, and high investments in R&D activities. The region is home to leading CMOs and technology providers that offer cutting-edge capabilities in biologics, mRNA, and viral vector vaccine production, making it a hub for innovations and large-scale manufacturing. Stringent regulatory frameworks ensure high standards of quality and compliance, which enhances trust in vaccines manufactured in the region. Additionally, the presence of a well-established healthcare system, government funding for immunization programs, and strong academic-industry collaborations are accelerating vaccine development and outsourcing activities. In March 2025, Canada revealed a commitment of CAD 675 Million in fresh funding for Gavi, the Vaccine Alliance's upcoming strategic phase from 2026 to 2030, known as 'Gavi 6.0.' The commitment will aid Gavi's goal to safeguard a greater number of individuals from more diseases at an accelerated pace.

KEY REGIONAL TAKEAWAYS:

UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The United States holds 88% of the market share in North America. The United States vaccine contract manufacturing market is primarily driven by the increasing prevalence of infectious diseases and the resurgence of certain vaccine-preventable illnesses. In line with this, the growing public and private investments in strengthening domestic manufacturing infrastructure and capacity are fueling the market expansion. As such, in April 2025, Merck initiated the development of a USD 1 Billion, 470,000-square-foot biologics facility in Wilmington, Delaware to manufacture KEYTRUDA and future therapies, resulting in over 500 permanent jobs and enhancing US manufacturing and innovation capabilities. Similarly, the broadening of novel vaccine platforms, including mRNA, recombinant, and vector-based technologies, is bolstering the market growth. The heightened need to meet stringent regulatory standards is also encouraging pharmaceutical companies to collaborate with experienced CMOs for compliance and quality assurance. Additionally, continual advancements in single-use bioprocessing technologies, improving production flexibility and reducing timelines, are propelling the market growth. The heightened focus on pandemic preparedness and vaccine stockpiling is driving long-term outsourcing contracts. Furthermore, the rise of personalized and therapeutic vaccines is diversifying service requirements, while the United States' skilled biologics workforce continues to attract global manufacturing partnerships.

EUROPE VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The European market is experiencing growth due to rising demand for pandemic preparedness measures, encouraging governments to establish large-scale production partnerships. In accordance with this, the increasing focus on regional self-sufficiency in vaccine supply is driving localized production agreements. The rising presence of strong biopharmaceutical hubs in Germany, Belgium, and the Netherlands, which are attracting significant investments in advanced facilities, is fostering the market expansion. Accordingly, in June 2025, Leyden Labs obtained EUR 20 Million from the European Investment Bank through HERA Invest to promote its pan-influenza nasal spray and pandemic readiness initiatives, aiding EU biodefense, antibiotic resistance, and respiratory virus safety projects. Moreover, ongoing advancements in bioprocessing technologies are improving scalability, efficiency, and quality standards. The heightened regulatory requirements are also motivating pharmaceutical companies to partner with experienced CMOs to ensure compliance. Furthermore, the rising prevalence of infectious diseases and the sustained demand for large-volume manufacturing are supporting the market growth. Besides this, the expansion of Europe's vaccine pipeline is diversifying service needs, creating lucrative opportunities in the market.

ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The Asia-Pacific market for vaccine contract manufacturing is largely influenced by the rapid broadening of national immunization programs. Similarly, the growing pipeline of next-generation vaccines, including mRNA, recombinant, and vector-based platforms, is fostering opportunities for specialized CMOs. The strategic collaborations between multinational pharmaceutical companies and regional manufacturers are accelerating technology transfer and ensuring compliance with global quality standards. Similarly, heightened focus on pandemic preparedness, prompting long-term manufacturing partnerships to secure supply resilience, is propelling the market growth. The region's cost advantages in skilled labor, raw materials, and operational efficiency are also attracting global outsourcing projects. Moreover, Asia Pacific's rising role as a competitive hub for vaccine production and export is reinforcing its prominence in the market. As such, in January 2025, Bharat Biotech allocated INR 1,500 Crore to establish a vaccine hub in Odisha that would produce eight Billion doses each year, generate 3,500 jobs, and manufacture vaccines for cholera, malaria, and polio, with plans for Chikungunya and Zika vaccines in the future.

LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

In Latin America, the market is advancing due to the expansion of government-led immunization programs aimed at achieving greater regional vaccine self-sufficiency. The Ministry of Health in Brazil announced that starting in 2026, 60 Million dengue vaccine doses will be manufactured annually. The initial phase will focus on people between the ages of 2 and 59, with an investment of BRL 68 Million allocated for the first production. Furthermore, rising investments in biopharmaceutical infrastructure, particularly in Brazil and Mexico, are strengthening large-scale production capacity. Additionally, strategic technology transfer agreements with multinational pharmaceutical companies are enabling the utilization of advanced manufacturing platforms and adherence to global quality standards.

MIDDLE EAST AND AFRICA VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The Middle East and Africa market is accumulating traction due to government-led initiatives aimed at promoting regional vaccine production capacity and decreasing dependence on imports. In addition to this, numerous collaborations with global pharmaceutical companies, enabling access to advanced manufacturing technologies and regulatory expertise, are impelling the market growth. Similarly, the increasing prevalence of infectious diseases is driving the demand for locally produced vaccines to ensure a timely supply for national immunization programs. Apart from this, expanded public health funding is strengthening long-term vaccine manufacturing sustainability across the region. Accordingly, in June 2025, the Department of Health in Abu Dhabi sealed agreements with Sanofi, Boehringer Ingelheim, and Abbott to enhance vaccine production, promote R&D activities, localize drug manufacturing, and reinforce the Emirate's international life sciences standing.

COMPETITIVE LANDSCAPE:

Key players are providing the technical expertise, infrastructure, and scalability needed to meet the growing global demand. These companies are investing heavily in advanced bioprocessing technologies, quality control systems, and regulatory compliance, enabling pharmaceutical and biotech firms to outsource vaccine production with confidence. By offering specialized capabilities, such as mRNA, viral vector, and recombinant vaccine manufacturing, key players are helping to accelerate development timelines and ensure consistent product quality. Their global presence also allows flexible capacity and localized production, improving supply chain resilience and accessibility. Moreover, strategic collaborations, joint ventures, and partnerships with innovators are strengthening the market by expanding service portfolios. In this way, key players act as enablers, ensuring efficiency, affordability, and speed in vaccine manufacturing. For instance, in October 2024, LenioBio collaborated with ReciBioPharm to broaden its CEPI-supported ALiCE cell-free protein expression technology for quicker vaccine manufacturing. The partnership involved transferring technology to Portugal for manufacturing at a 10-liter scale, aiding the 100 Days Mission to expedite the development of vaccines and preparedness for new health challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the vaccine contract manufacturing market?

2. What is the future outlook of vaccine contract manufacturing market?

3. What are the key factors driving the vaccine contract manufacturing market?

4. Which region accounts for the largest vaccine contract manufacturing market share?

5. Which are the leading companies in the global vaccine contract manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2025
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2025
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2025
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million USD), 2026-2034
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players